BioSpace News Archive

Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.

Galapagos NV announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer.

Inari Medical, Inc. announced that its management team will present at the Bank of America 2023 Healthcare Conference on Tuesday, May 9, 2023 at 3:00 p.m. Pacific Time at the Encore Hotel in Las Vegas.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones.

Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company) today reported first quarter financial results for the period ended March 31, 2023.

Acumen Pharmaceuticals, Inc. announced that the Company will report first quarter financial results on Tuesday, May 9, 2023.

Biomea Fusion, Inc. reported first quarter 2023 financial results and business highlights.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2023.

Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies.

Personalis, Inc. announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial, B-STRONGER-1, to evaluate the clinical performance of the NeXT Personal® test for detecting minimal residual disease during and after treatment and recurrent cancer in patients with early-stage resectable triple-negative breast cancer.